|
Video: What is a Stock Split?
|
|
Phathom Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases. Co.'s primary product candidate, vonoprazan, is an oral small molecule potassium-competitive acid blocker (P-CAB). P-CABs are a class of medicines that block acid secretion in the stomach. Vonoprazan has shown effects and has demonstrated clinical results as an agent in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of H. pylori infection. According to our PHAT split history records, Phathom Pharmaceuticals has had 0 splits. | |
|
Phathom Pharmaceuticals (PHAT) has 0 splits in our PHAT split history database.
Looking at the PHAT split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Phathom Pharmaceuticals shares, starting with a $10,000 purchase of PHAT, presented on a split-history-adjusted basis factoring in the complete PHAT split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
10/28/2019 |
|
End date: |
03/27/2024 |
|
Start price/share: |
$23.59 |
|
End price/share: |
$11.05 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-53.16% |
|
Average Annual Total Return: |
-15.78% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$4,683.83 |
|
Years: |
4.42 |
|
|
|
|
|